Navigation Links
Published Results Using AtriCure Minimally Invasive Products
Date:10/16/2007

WEST CHESTER, Ohio, Oct. 16 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation products, today announced that results reporting on the Company's proprietary minimally invasive products, which physicians have adopted to treat atrial fibrillation (AF), were published in the Journal of Cardiovascular Electrophysiology by Dr. James H. McClelland, an electrophysiologist, and colleagues from the Oregon Heart and Vascular Institute.

The authors reported the results from 20 AF patients. Based on the use of 30-day continuous monitoring at one-year follow-up, 87.5% of the paroxysmal and persistent AF patients and 75% of overall patients were free from AF and left atrial arrhythmias and were also off anti-arrhythmic drugs. There were no reports of major complications.

Dr. James H. McClelland commented, "These data suggest that epicardial bipolar ablation, along with guided ablation of the ganglionic plexi, is a promising potential treatment for patients with paroxysmal and persistent AF and a more extensive ablation treatment is likely required to treat patients with more permanent forms of AF."

"These results support our confidence in our ability to expand the treatment options for those patients who suffer from AF and our commitment to pursuing AF approvals for our products from the Food and Drug Administration (FDA)," said David J. Drachman, AtriCure's President and Chief Executive Officer. "During the first quarter of 2008, we have plans to investigate new products which will expand the ablation procedure. We believe that these new products will provide a superior treatment alternative for persistent and permanent AF patients, patients w
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Largest Ever Study of Genetics Behind Common Diseases Published
2. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
3. Findings on Dangerous Parasite, Toxoplasma Gondii Published
4. Siddha Medicine Texts to Be Published in English
5. Experimental treatment for Ebola Virus Shows promising results in mice
6. Hormone Deficiency Results In Miscarriage
7. Gleevec gets hopeful results
8. Breast Implants May Interfere With The Interpretation Of Mammogram Results
9. DNA Testing For More Accurate Results
10. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
11. IVF results may be affected by stress and other related factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)... , CHAMPAIGN, Ill. Many older Americans may be s...cial Security too soon, according to a University ...irement program for nearly two decades. , More t...ly Social Security checks for life by claiming ben...tter understood the program,s options and conseque...
(Date:9/4/2008)... Officials want stronger labeling about fungal in...lthDay News) -- Federal health authorities have as...ppressive drugs to bolster safety warnings on the .... , The drugs, Humira, Cimzia, Enbrel and Remic...or necrosis factor alpha blockers (TNF-alpha block...
(Date:9/4/2008)... PACIFIC PALISADES, Calif., Sept. 4 /PRNewswi...r and recognized authority in the field of weight,... "Who,s Who in,California," "Who,s Who in The West...," "Who,s Who in Medicine and Health Care" and oth...evote his expertise to exposing the,inaccurate, mi...
(Date:9/4/2008)... HARRISBURG, Pa., Sept. 4 /PRNewswire-USNewsw...ely 250 individuals, organizations, and community,...Pennsylvania, has added,an interactive map to its ...f the water they drink contains the optimal level ...alf of Pennsylvania,s citizens currently have opti...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:PA Fluoride NOW Debuts Interactive Map for Residents to Learn if Their Water Has the Best Fluoride Level to Protect Teeth 2Health News:PA Fluoride NOW Debuts Interactive Map for Residents to Learn if Their Water Has the Best Fluoride Level to Protect Teeth 3
...0% of youth in the United States cannot boast of a...e case with nearly 15 million// American adults wh...cession. A report from the Agency for Healthcare ...mericans who were not covered under health insuran...
... good trend of decline in the number of suicides. ...realize its goal of scaling down the suicide rates...ealth has enabled some Statistics which portray th... per 100,000 and in 2004 it had dropped to 8.56 de...
...rgos, has confirmed that a new hospital for the Be... Stating that he has directed the Area Health Se...g process for a new hospital. Stating that they wi...future health needs of the Bega community in order...
...’s or KFC restaurants, across the world, have vary...an the levels of the same // food elsewhere. Accor...ew England Journal of Medicine, the researchers an...d's chicken nuggets, KFC hot wings, french fries f...
Other Medicine News:Health News:Construction Of A New Hospital In The Bega Area Confirmed 2
(Date:9/6/2008)...rcent or Greater Concordance Compared to FISH ..., - Company to Include Reporting for HER2 Gene Exp...Reports by End of 2008 -, REDWOOD CITY, Calif., S...nc. (Nasdaq: GHDX ) today announced results from ...ing for HER2 gene expression, as measured by the,c...
(Date:9/5/2008).../PRNewswire-USNewswire/ -- The Florida,Technology,...lorida,Atlantic University researcher Dr. Herbert ... the Center for Molecular Biology and,Biotechnolog...d CHS,Resources LLC (CHS), $184,294 as part of the...tance Grant program (SURECAG). SURECAG was,establi...
(Date:9/5/2008)...., Sept. 5 /- SARcode,Corpo...e LFA-1 inhibitors,to treat inflammatory diseases,...today announced SARcode,s initiation of a Phase 1 ...andidate for T-cell mediated ophthalmic,diseases. ...nt providing,SARcode with an exclusive license to ...
(Date:9/4/2008).... 4 /- Cytopia Limited (ASX:,CYT) tod...ts Phase Ib/II,study of CYT997, the company,s nove...s with an aggressive form of brain cancer known as... trial is the first Phase II efficacy study in hig...any and the second in its,suite of Phase II studie...
Breaking Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 4472 1ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 4472 2Immunosyn Corporation to Present at FSX 1465 1Immunosyn Corporation to Present at FSX 1465 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 1New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 3New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 4A new key to detecting deadly aortic aneurysms 4466 1A new key to detecting deadly aortic aneurysms 4466 2
...tudy Fails to Meet Primary Endpoint of Improvement... 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics...H, the Company,s pivotal Phase 3 study of Efaproxy...y (WBRT) in women,with brain metastases originatin...its primary endpoint of demonstrating a,statistica...
...SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ --...l company committed to,the discovery, development ...reatment of hepatitis and cancer, announced today ...inical development as an,orally-administered direc... C virus (HCV) infection. , "We have identified a ...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
Aire-Cuf® and Fome-Cuf® tracheostomy tubes with talk attachment are available in I.D. sizes from 5.0 mm to 9.5 mm. , ,Developed to aid the ventilator dependent patient in communicating with
For additional patient safety, the laryngectomy tube is designed with an integral 15 mm ISO termination that can be connected to a ventilator, with or without the inner cannula in place , ,Portex&re
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig
...® Mid-Range Aire-Cuf® Adjustable Neck Flan...he TTS™ tube except this tube features the m...g;., ,Adult Mid-Range Aire-Cuf® Adjustable Ne...ude a trach tie, disconnect wedge, and obturator/i...
Medicine Products: